- 口服有效
- 低生體可用率
- non-peptidomimetic prodrug
- 可逆抑制 free and fibrin-bound thrombins
- 增加 GI bleeding 風險
- 解毒
	- Idarucizumab
![[Pasted image 20231014225649.png|300]]
![[Pasted image 20231014230015.png|300]]